Our findings also corroborate that immunotherapies with PD-1 and/or CTLA-4 blockade, should be able to overcome resistance and broaden the clinical benefit, especially for CYT-high skin melanoma patients. This evidence concerns the gene CTLA4 and cutaneous melanoma.